Axelrad JE, Lichtiger S, Yajnik V Inflammatory bowel disease and cancer: The role of inflammation, immunosuppression, and cancer treatment. World J Gastroenterol. 2016 May 28;22(20):4794-801. doi: 10.3748/wjg.v22.i20.4794. Review.
Baumgart DC, Carding SR Inflammatory bowel disease: cause and immunobiology. Lancet. 2007 May 12;369(9573):1627-40. Review.
Baumgart DC, Sandborn WJ Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet. 2007 May 12;369(9573):1641-57. Review.
Bennike T, Birkelund S, Stensballe A, Andersen V Biomarkers in inflammatory bowel diseases: current status and proteomics identification strategies. World J Gastroenterol. 2014 Mar 28;20(12):3231-44. doi: 10.3748/wjg.v20.i12.3231. Review.
Cario E Toll-like receptors in inflammatory bowel diseases: a decade later. Inflamm Bowel Dis. 2010 Sep;16(9):1583-97. doi: 10.1002/ibd.21282. Review.
Casanova JL, Abel L Revisiting Crohn's disease as a primary immunodeficiency of macrophages. J Exp Med. 2009 Aug 31;206(9):1839-43. doi: 10.1084/jem.20091683. Epub 2009 Aug 17. Review.
Charlebois A, Rosenfeld G, Bressler B The Impact of Dietary Interventions on the Symptoms of Inflammatory Bowel Disease: A Systematic Review. Crit Rev Food Sci Nutr. 2016 Jun 10;56(8):1370-8. doi: 10.1080/10408398.2012.760515. Review.
Clevers H Inflammatory bowel disease, stress, and the endoplasmic reticulum. N Engl J Med. 2009 Feb 12;360(7):726-7. doi: 10.1056/NEJMcibr0809591.
Colman RJ, Rubin DT Fecal microbiota transplantation as therapy for inflammatory bowel disease: a systematic review and meta-analysis. J Crohns Colitis. 2014 Dec;8(12):1569-81. doi: 10.1016/j.crohns.2014.08.006. Epub 2014 Sep 13. Review.
Coskun M Intestinal epithelium in inflammatory bowel disease. Front Med (Lausanne). 2014 Aug 25;1:24. doi: 10.3389/fmed.2014.00024. eCollection 2014. Review.
Dave M, Mehta K, Luther J, Baruah A, Dietz AB, Faubion WA Jr Mesenchymal Stem Cell Therapy for Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. Inflamm Bowel Dis. 2015 Nov;21(11):2696-707. doi: 10.1097/MIB.0000000000000543. Review.
Del Pinto R, Pietropaoli D, Chandar AK, Ferri C, Cominelli F Association Between Inflammatory Bowel Disease and Vitamin D Deficiency: A Systematic Review and Meta-analysis. Inflamm Bowel Dis. 2015 Nov;21(11):2708-17. doi: 10.1097/MIB.0000000000000546. Review.
Dessein R, Chamaillard M, Danese S Innate immunity in Crohn's disease: the reverse side of the medal. J Clin Gastroenterol. 2008 Sep;42 Suppl 3 Pt 1:S144-7. doi: 10.1097/MCG.0b013e3181662c90. Review.
Feller M, Huwiler K, Schoepfer A, Shang A, Furrer H, Egger M Long-term antibiotic treatment for Crohn's disease: systematic review and meta-analysis of placebo-controlled trials. Clin Infect Dis. 2010 Feb 15;50(4):473-80. doi: 10.1086/649923. Review.
Ghouri YA, Richards DM, Rahimi EF, Krill JT, Jelinek KA, DuPont AW Systematic review of randomized controlled trials of probiotics, prebiotics, and synbiotics in inflammatory bowel disease. Clin Exp Gastroenterol. 2014 Dec 9;7:473-87. doi: 10.2147/CEG.S27530. eCollection 2014. Review.
Gilardi D, Fiorino G, Genua M, Allocca M, Danese S Complementary and alternative medicine in inflammatory bowel diseases: what is the future in the field of herbal medicine? Expert Rev Gastroenterol Hepatol. 2014 Sep;8(7):835-46. doi: 10.1586/17474124.2014.917954. Epub 2014 May 12. Review.
Kristo I, Stift A, Bergmann M, Riss S Surgical recurrence in Crohn's disease: Are we getting better? World J Gastroenterol. 2015 May 28;21(20):6097-100. doi: 10.3748/wjg.v21.i20.6097. Review.
Lalande JD, Behr MA Mycobacteria in Crohn's disease: how innate immune deficiency may result in chronic inflammation. Expert Rev Clin Immunol. 2010 Jul;6(4):633-41. doi: 10.1586/eci.10.29. Review.
Mahadeva U, Martin JP, Patel NK, Price AB Granulomatous ulcerative colitis: a re-appraisal of the mucosal granuloma in the distinction of Crohn's disease from ulcerative colitis. Histopathology. 2002 Jul;41(1):50-5.
Maloy KJ, Powrie F Intestinal homeostasis and its breakdown in inflammatory bowel disease. Nature. 2011 Jun 15;474(7351):298-306. doi: 10.1038/nature10208. Review.
Naser SA, Sagramsingh SR, Naser AS, Thanigachalam S Mycobacterium avium subspecies paratuberculosis causes Crohn's disease in some inflammatory bowel disease patients. World J Gastroenterol. 2014 Jun 21;20(23):7403-15. doi: 10.3748/wjg.v20.i23.7403. Review.
Smart HL, Mayberry JF, Atkinson M Alternative medicine consultations and remedies in patients with the irritable bowel syndrome. Gut. 1986 Jul;27(7):826-8.
Thomas S, Baumgart DC Targeting leukocyte migration and adhesion in Crohn's disease and ulcerative colitis. Inflammopharmacology. 2012 Feb;20(1):1-18. doi: 10.1007/s10787-011-0104-6. Epub 2011 Dec 20. Review.
Trikudanathan G, Venkatesh PG, Navaneethan U Diagnosis and therapeutic management of extra-intestinal manifestations of inflammatory bowel disease. Drugs. 2012 Dec 24;72(18):2333-49. doi: 10.2165/11638120-000000000-00000. Review.
Walker MM, Murray JA An update in the diagnosis of coeliac disease. Histopathology. 2011 Aug;59(2):166-79. doi: 10.1111/j.1365-2559.2010.03680.x. Epub 2010 Nov 3. Review.
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.